Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	6.88	8.1	9.52	11.93	10.88
Research & Development	16.53	24.47	29.12	31.83	37.98
Other Operating Expenses	0	-0.02	0	0	0
Operating Expenses	23.41	32.54	38.63	43.76	48.85
Operating Income	-23.41	-32.54	-38.63	-43.76	-48.85
Other Expense / Income	3.62	8.76	4.61	-37.77	-2.18
Pretax Income	-27.03	-41.31	-43.24	-6	-46.67
Net Income	-27.03	-41.31	-43.24	-6	-46.67
Shares Outstanding (Basic)	48	47	42	29	29
Shares Outstanding (Diluted)	48	47	42	29	29
Shares Change	3.16%	11.23%	41.98%	0.44%	6.69%
EPS (Basic)	-0.56	-0.89	-1.03	-0.20	-1.59
EPS (Diluted)	-0.56	-0.89	-1.03	-0.20	-1.59
Free Cash Flow	-23.97	-27.27	-36.72	-34.85	-37.35
Free Cash Flow Per Share	-0.50	-0.59	-0.88	-1.18	-1.27
EBITDA	-26.88	-40.94	-42.78	-5.36	-45.93
Depreciation & Amortization	0.15	0.37	0.46	0.63	0.74
EBIT	-27.03	-41.31	-43.24	-6	-46.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).